Treatment differences and long-term outcomes in adults and children with Ewing sarcoma

• Published in: Cancer epidemiology 2024-10, Vol.92, p.102653, Article 102653
• Main Authors: Hajjaj, Omar I., Corke, Lauren, Strahlendorf, Caron, Hamilton, Sarah Nicole, Feng, Xiaolan, Simmons, Christine E.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Adults; Age; Aged; bone; Bone Neoplasms - drug therapy; Bone Neoplasms - mortality; Bone Neoplasms - pathology; Bone Neoplasms - therapy; British Columbia - epidemiology; Cancer therapies; Charlson Comorbidity Index; Chemotherapy; Child; Child, Preschool; Children; Comorbidity; Compression; Ewing sarcoma; Ewing's sarcoma; Ewings sarcoma; Female; Humans; Male; Malignancy; Medical prognosis; Metastasis; Middle Aged; Population; Radiation therapy; Retrospective Studies; Sarcoma, Ewing - drug therapy; Sarcoma, Ewing - mortality; Sarcoma, Ewing - pathology; Sarcoma, Ewing - therapy; soft tissue; Survival; Survival Rate; Toxicity; Treatment Outcome; Young Adult
• ISSN: 1877-7821; 1877-783X; 1877-783X
• DOI: 10.1016/j.canep.2024.102653

Ewing sarcoma is an aggressive malignancy primarily affecting children and adolescents. Limited research is available on treatment practices, clinical course, and survival in adults. A multi-institution retrospective cohort study of all adults (>18 years) and children (≤18 years) with Ewing sarcoma treated in British Columbia, Canada between January 01, 2000 and December 31, 2018. One-hundred seven individuals (66 adults, 41 children) were included in the analysis. 5-year OS was 58 % in adults and 75 % in children. For individuals with local disease, 5-year OS was 74 % in adults and 84 % in children. Adult status was associated with impaired PFS (HR, 1.8; 95 % CI, 1.0 – 3.1, p=0.04) and OS (HR, 1.8; 95 % CI, 0.9 – 3.5; p=0.088). A Charlson Comorbidity Index (CCI) ≥3 was associated with impaired survival in adults and children (HR, 3.9, 95 % CI, 2.0 – 7.5; p=